Provided by Tiger Fintech (Singapore) Pte. Ltd.

Annovis Bio, Inc.

1.61
+0.04002.55%
Post-market: 1.670.0600+3.73%19:40 EDT
Volume:677.23K
Turnover:1.13M
Market Cap:31.37M
PE:-0.70
High:1.75
Open:1.59
Low:1.57
Close:1.57
Loading ...

Company Profile

Company Name:
Annovis Bio, Inc.
Exchange:
NYSE
Establishment Date:
2008
Employees:
12
Office Location:
101 Lindenwood Drive,Suite 225,Malvern,Pennsylvania,United States
Zip Code:
19355
Fax:
- -
Introduction:
Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead product candidate is Buntanetap, which is in Phase 3 clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, and other chronic neurodegenerative diseases. It is also developing ANVS405 for protecting the brain after traumatic brain injury and/or stroke; and ANVS301, which is in Phase I clinical trials to increase cognitive capability in later stages of AD and dementia. The company was incorporated in 2008 and is based in Berwyn, Pennsylvania.

Directors

Name
Position
Michael Hoffman
Chairman of the Board
Maria Maccecchini
Founder, President and CEO and director
Claudine Bruck
Director
Mark White
Director
Robert Whelan
Director

Shareholders

Name
Position
Jeffrey McGroarty
Chief Financial Officer
Maria Maccecchini
Founder, President and CEO and director